Viyash Scientific (512529) Q1 26/27 earnings summary

Executive summary

• Q1 FY27 delivered strong results with revenue from operations at INR 946 crore (₹9,463.6 million), up 20% year-over-year, and EBITDA at INR 205 crore, up 59% year-over-year, with margin expansion to 21.6%.

• Profit after tax more than doubled to INR 79 crore (₹792.9 million), and net debt reduced to INR 86 crore, making the company virtually debt-free.

• Integration of recent acquisitions and amalgamation of subsidiaries completed, positioning for further organic and inorganic growth.

• Acquisition of Bio For Life in Italy strengthens presence in the companion animal segment and provides access to key European markets.

• Focus remains on disciplined execution, operational efficiency, and strategic investments for sustainable growth.

Financial highlights

• Revenue from operations grew 19.5% year-over-year and 2.9% sequentially to INR 946 crore (₹9,463.6 million).

• Adjusted EBITDA rose 59.2% year-over-year to INR 205 crore (2,047 Mn), with margin at 21.6% (up from 16.2%).

• Profit after tax up 115% year-over-year to INR 79 crore (₹792.9 million).

• Finance cost declined to INR 12.5 crore from INR 20.4 crore year-over-year.

• Basic EPS (consolidated) for Q1 FY27 was ₹1.51, up from ₹0.74 (restated) in Q1 FY26.

Outlook and guidance

• Sustained double-digit revenue growth and EBITDA margins of 20%-22% expected to continue.

• API business anticipated to grow over 20% in animal health and 13%-15% overall, with stronger growth from 2029 as new products launch.

• Targeting $1 billion revenue by 2032, implying an 18% CAGR from FY 2027.

• Incorporation of Alivira Vietnam Company Limited planned to expand animal health business in Vietnam.